BioNTech SEBNTXEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
Revenue
$260.8M
Gross Profit
$256.7M
Operating Profit
$-501.1M
Net Profit
$-386.6M
Gross Margin
98.4%
Operating Margin
-192.1%
Net Margin
-148.2%
YoY Growth
N/A
Financial Flow
BioNTech SE Q2 2025 Financial Summary
BioNTech SE reported revenue of $260.8M for Q2 2025, with a net profit of $-386.6M (-148.2% margin). Cost of goods sold was N/A.
Key Financial Metrics
| Total Revenue | $260.8M |
|---|---|
| Net Profit | $-386.6M |
| Gross Margin | N/A |
| Operating Margin | -192.1% |
| Report Period | Q2 2025 |
BioNTech SE Quarterly Revenue & Net Profit History
BioNTech SE results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 2025 | $1.5B | — | $-28.7M | -1.9% |
| Q2 2025 | $260.8M | — | $-386.6M | -148.2% |
| Q1 2025 | $182.8M | — | $-415.8M | -227.5% |
| Q3 2024 | $1.2B | — | $198.1M | 15.9% |
| Q2 2024 | $128.7M | — | N/A | N/A |
| Q1 2024 | $187.6M | — | N/A | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $187.6M | $128.7M | $1.24B | $182.8M | $260.8M | $1.52B |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | N/A | N/A | N/A | N/A | N/A | N/A |
Cash Flow
No data available for this period